# Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

> **NCT04765657** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 345 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** inclisiran sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04765657
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2022-06-09
- **Final completion:** 2026-12-28
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765657, "Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04765657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*